Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GeneDx Holdings ( (WGS) ) has shared an update.
On February 27, 2026, GeneDx Holdings Corp. entered into a new $100 million term loan agreement with affiliates of Blackstone and other lenders, replacing its prior credit facility dated October 27, 2023. The funding, which carries a floating interest rate based on Term SOFR plus 4.50% with a 1.50% floor and matures five years from closing, was used to fully repay the existing term loan and is also earmarked for balance sheet optimization and general corporate purposes.
The facility is secured by a first lien on substantially all assets of GeneDx and its guarantor subsidiaries, includes mandatory prepayment triggers tied to change of control, additional indebtedness and certain asset sales, and features a $50 million minimum liquidity covenant. The agreement’s covenants and default provisions underscore lender protections while providing GeneDx with financial flexibility to manage its capital structure and operating obligations, with any continuing event of default allowing lenders to accelerate all outstanding amounts.
The most recent analyst rating on (WGS) stock is a Buy with a $170.00 price target. To see the full list of analyst forecasts on GeneDx Holdings stock, see the WGS Stock Forecast page.
Spark’s Take on WGS Stock
According to Spark, TipRanks’ AI Analyst, WGS is a Neutral.
The score is driven primarily by improving financial performance (margin expansion and positive TTM operating/FCF) and strong, reaffirmed 2026 guidance with positive management sentiment. Offsetting these positives are weak technicals (price below key moving averages with negative MACD) and a very high P/E with no dividend yield support.
To see Spark’s full report on WGS stock, click here.
More about GeneDx Holdings
GeneDx Holdings Corp. operates in the healthcare and life sciences sector, providing genetic testing and related diagnostic services. The company focuses on leveraging advanced genomics to support precision medicine, working with patients, clinicians and healthcare systems that require specialized diagnostic insights for complex genetic conditions.
Average Trading Volume: 635,270
Technical Sentiment Signal: Sell
Current Market Cap: $2.33B
Find detailed analytics on WGS stock on TipRanks’ Stock Analysis page.